NCT03432260 - A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

September 9, 2019

Study Completion Date

September 9, 2019

Conditions

Alcoholic Hepatitis

Interventions

DRUG

DUR-928 30 mg

Lowest dose of 3 dose escalation arms.

DRUG

DUR-928 90 mg

Middle dose of 3 dose escalation arms.

DRUG

DUR-928 150 mg

Highest dose of 3 dose escalation arms.

Trial Locations (7)

DURECT Study Site 0004, Atlanta

DURECT Study Site 007, Miami

DURECT Study Site 0005, Louisville

DURECT Study Site 008, Indianapolis

DURECT Study Site 0002, Chicago

DURECT Study Site 006, San Antonio

DURECT Study Site 0001, San Diego